<DOC>
	<DOC>NCT01474278</DOC>
	<brief_summary>This multi-center, randomized, double-blind study will evaluate exploratory biomarkers and the safety and tolerability of a single dose of RO5028442 in adult male high-functioning autistic patients. In a cross-over design, patients will be randomized to receive either a single dose of RO5028442 or matching placebo with a washout period of 7-14 days. Anticipated time on study is up to approximately 9 weeks.</brief_summary>
	<brief_title>A Study of RO5028442 in Adult Male High-Functioning Autistic Patients</brief_title>
	<detailed_description />
	<mesh_term>Autistic Disorder</mesh_term>
	<criteria>Patients with a diagnosis of Autistic Disorder as defined by DSMIV, confirmed by the team and supported with the Autistic Diagnostic Observation Schedule (ADOS) Male adults, 18 to 45 years of age IQ &gt; 70 (Wechsler Adult Intelligence ScaleFull scale) Body mass index (BMI) 18 to 35 kg/m2 inclusive Aberrant Behavior Checklist (ABC) Irritability subscale score &lt;/= 13 Positive urine test for drugs of abuse Alcohol and/or substance abuse/dependence during the last 12 months Positive for hepatitis B, hepatitis C or HIV infection Clinically relevant cardiovascular, renal, hepatic or hematologic disease or disorder Active inflammatory pulmonary disease History of epilepsy/seizure disorder (except for simple febrile seizures) Initiation of new or major change in psychosocial intervention within 4 weeks prior to randomization Treatment with any investigational agent within 90 days prior to screening History of hypersensitivity or allergic reactions</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>